MENU

Presence or Absence of Colorectal Adenomas Influences Efficacy of Chemoprevention

September 10, 2018

Chang and colleagues examined the cancer preventive activity of the cholesterol-lowering agent atorvastatin – the generic form of Lipitor – alone and in combination with the anti-inflammatory drug sulindac in mice confirmed by colonoscopy to be tumor-free or bearing colorectal tumors at 7-8 weeks of age. After 14 weeks of treatment, atorvastatin completely eliminated the formation of microadenomas.Chang and colleagues examined the cancer preventive activity of the cholesterol-lowering agent atorvastatin – the generic form of Lipitor – alone and in combination with the anti-inflammatory drug sulindac in mice confirmed by colonoscopy to be tumor-free or bearing colorectal tumors at 7-8 weeks of age. After 14 weeks of treatment, atorvastatin completely eliminated the formation of microadenomas.

PHILADELPHIA (September 10, 2018)— Chemoprevention was effective in reducing the incidence of colorectal cancer in a new study, but the therapies worked differently depending on whether mice presented with or without benign tumors at the time the intervention started. The paper, by Wen-Chi Chang, PhD, an assistant research professor at Fox Chase Cancer Center, appears online in Gut, a peer-reviewed journal published by BMJ.

Chang and colleagues examined the cancer preventive activity of the cholesterol-lowering agent atorvastatin – the generic form of Lipitor – alone and in combination with the anti-inflammatory drug sulindac in mice confirmed by colonoscopy to be tumor-free or bearing colorectal tumors at 7-8 weeks of age. After 14 weeks of treatment, atorvastatin completely eliminated the formation of microadenomas, the earliest detectable lesions in the development of colon adenomas, in tumor-free mice. In contrast, the combination treatment reduced the number of colon adenomas only in mice that had colon tumors at the time of study enrollment.

“These results indicate that physicians need to consider the prior colon tumor history of a high risk subject when selecting a chemopreventive regimen, to ensure that the protection afforded is optimal,” said Margie Clapper, co-leader of the Cancer Prevention and Control Program at Fox Chase and senior author of the study.

Funding supported by an appropriation from the Commonwealth of Pennsylvania, a donation from Aurora M and Timothy P Hughes, and by grants CA-129467 and  
CA-006927 from the National Cancer Institute, which is part of the National Institutes of Health.

       

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. 
For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Connect with Fox Chase